A Pilot Study of PET/MR for Rectal Cancer Treatment Monitoring and Surveillance
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Rectal Cancer
- Sponsor
- Washington University School of Medicine
- Enrollment
- 14
- Locations
- 1
- Primary Endpoint
- Technical Feasibility of PET/MRI as Measured by the Completion of the Study With Acceptable Image Quality in ≥70% of Scans
- Status
- Terminated
- Last Updated
- 3 years ago
Overview
Brief Summary
The goal of pilot study is to assess the feasibility of FDG-PET/MRI for monitoring rectal cancer disease status in the setting of rectal cancer non-operative management (NOM). Data from this study will be used to guide the design of future clinical trials involving FDG-PET/MRI for rectal cancer NOM.
Investigators
Eligibility Criteria
Inclusion Criteria
- •At least 18 years of age
- •Biopsy-proven rectal adenocarcinoma of the rectum with clinically suspected or previously known stage I-IIIB (cT1-4, N0-2, M0) disease
- •Anticipated or prior chemoradiation as part of an NOM treatment strategy
- •Ability to understand and willingness to sign an IRB-approved written informed consent document
Exclusion Criteria
- •Prior surgical resection of rectal cancer (endoscopic or TME)
- •Contraindication to MRI
- •Comorbidities that would limit patient's ability to cooperate with a PET/MRI examination (e.g. dementia, inability to follow commands, claustrophobia, tremors, requirement for oxygen by nasal cannula, etc...).
- •Implanted devices or materials that may interfere with MRI imaging or create significant artifact
- •Pregnancy
- •Contraindication to gadolinium contrast or FDG
- •End-stage renal disease
Outcomes
Primary Outcomes
Technical Feasibility of PET/MRI as Measured by the Completion of the Study With Acceptable Image Quality in ≥70% of Scans
Time Frame: Up to 12 months after completion of enrollment of all patients (26 months)
-For patients imaged at multiple time points after enrollment, all available PET/MRIs will be included in the feasibility analysis. Patients able to remain on the scanner for the full duration of the planned data acquisition without any serious adverse events will be considered to have completed the PET/MRI rectal cancer protocol. Image quality will be assessed by the Principal Investigator on review at a dedicated workstation with specialized PET/MR software. A standardized Likert-based scoring scheme will be utilized to capture subjective assessments of image contrast (1 = worst; 5 = best), image resolution (1 = worst; 5 = best), and image artifact 'freeness' (1 = worst; 5 = best). Image sets scoring ≥ 3 in all three categories will be considered of acceptable quality.
Secondary Outcomes
- Percentage of Scans With Changes in Perceived Disease Status as Measured by PET/MRI Tumor Regression Grade Relative to the Conventional MRI Only Tumor Regression Grade(Up to 12 months after completion of enrollment of all patients (26 months))